Skip to main content
. 2012 Feb;80(2):679–687. doi: 10.1128/IAI.05826-11

Fig 2.

Fig 2

Bactericidal assays. (A) Percent survival of 35000HP, 35000HP-RSM208 (neuA mutant), 35000HP-RSM203 (lst mutant), and FX517 (dsrA mutant) in 50% NHS, calculated as follows: [(geometric mean CFU in active NHS/geometric mean CFU in heat-inactivated NHS) × 100]. P values are as follows: for 35000HP versus 35000HP-RSM208, P = 0.22; for 35000HP versus 35000HP-RSM203, P = 0.25; for 35000HP versus FX517, P = 0.001; for 35000HP-RSM208 versus 35000HP-RSM203, P = 0.057; for 35000HP-RSM208 versus FX517, P = 0.0004; and for 35000HP-RSM203 versus FX517, P = 0.0002. (B) Percent survival of 35000HP, 35000HP-RSM208, and FX517 grown in media supplemented with 1 mM Neu5Ac and FX517 grown without Neu5Ac supplementation in 50% NHS, calculated as described for panel A. P values are as follows: for 35000HP versus 35000HP-RSM208, P = 0.059; for 35000HP versus FX517 grown with Neu5Ac, P = 0.006; for 35000HP versus FX517 grown without Neu5Ac, P = 0.0001; for 35000HP-RSM208 versus FX517 grown with Neu5Ac, P < 0.0001; for 35000HP-RSM208 versus FX517 without Neu5Ac, P < 0.0001; and for FX517 grown with Neu5Ac versus FX517 grown without Neu5Ac, P = 0.16. For both panels, values are means ± SDs from 5 independent experiments.